Cary Street Partners Financial LLC Makes New Investment in AstraZeneca PLC $AZNCF

Cary Street Partners Financial LLC purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,365 shares of the company’s stock, valued at approximately $2,872,000.

A number of other hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC bought a new position in shares of AstraZeneca in the fourth quarter worth approximately $1,396,000. Burling Wealth Partners LLC bought a new position in shares of AstraZeneca in the fourth quarter worth about $4,532,000. Redmont Wealth Advisors LLC bought a new position in shares of AstraZeneca in the fourth quarter worth about $122,000. Elyxium Wealth LLC bought a new position in shares of AstraZeneca in the fourth quarter worth about $102,000. Finally, L & S Advisors Inc bought a new stake in AstraZeneca during the 4th quarter valued at approximately $14,863,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

Shares of AZNCF opened at $187.10 on Thursday. The business’s 50 day moving average is $187.10 and its 200 day moving average is $185.10. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.